UTAH MEDICAL PRODUCTS INC Annual Report - 2025 Performance Review

I’ve updated our guide with the final 2025 financial results. While the company remains a reliable cash generator, 2025 brought some growing pains and unexpected hurdles.

1. What does this company do?

UTMD designs and builds specialized medical devices for neonatal intensive care, labor and delivery, and women’s health. Their products include catheters, pressure monitors, and the Filshie Clip System for permanent sterilization. Founded in 1978 and based in Utah, the company focuses on high-quality tools that improve patient safety, such as devices that help minimize blood loss in premature infants.

2. A track record of stability

UTMD manages its money carefully. In 2025, the company returned about $4 million to shareholders through dividends. They also bought back 158,000 shares—about 4.5% of the company—showing that management believes the stock is a good value. With no long-term debt and full ownership of their factories in Utah and Ireland, they keep a tight grip on quality and supply chains. They also maintain a spotless record with the FDA.

3. Business performance: The 2025 Reality Check

2025 was a tougher year than 2024. Worldwide revenue dropped 6% to $38.5 million, and profit fell 19% to $11.1 million.

Three main issues caused this dip:

• The PendoTECH Split: UTMD ended a contract manufacturing deal with PendoTECH. This cut revenue by $2.3 million, but management made this choice to focus on their own higher-profit products.
• The China Distributor: A major distributor in China failed to pay what they owed. This resulted in a $700,000 hit to the company’s bottom line.
• Filshie Clip Sales: Sales for their signature sterilization device fell by $700,000 due to increased competition in elective surgeries.

4. Risks: The "Bureaucracy" Tax

Management is vocal about the hurdles small medical device companies face:

• Group Purchasing Organizations (GPOs): UTMD argues that GPOs act like cartels. By favoring cheap, generic goods, these groups make it hard for UTMD to sell its safer, specialized tools to hospitals.
• Regulatory Overload: New European Union rules (EU MDR) create high costs. These rules force smaller companies to pay for expensive recertifications or pull products from the market entirely.
• Legal Distractions: The company has never lost a product liability case in 33 years. Even so, they are still defending against lawsuits regarding the Filshie Clip. These legal costs weighed on profits throughout 2025.

5. Financial Health

Despite lower revenue, UTMD’s balance sheet is very strong. They finished 2025 with $85.8 million in cash and no debt. This cash pile protects them against market swings. Their profit margin remains healthy at 28.8%, meaning they keep about 29 cents of profit for every dollar of sales.

6. Future Outlook

Management is shifting toward selling only their own branded devices, moving away from contract manufacturing to boost long-term profits. With $85.8 million in cash and no debt, the company is well-positioned to handle regulatory challenges. By sticking to their 33-year history of operational excellence, UTMD remains a conservative, cash-focused company navigating a complex healthcare market.

Investor Takeaway: UTMD is a "fortress" company—they have zero debt and a massive cash pile, which makes them very safe during economic downturns. However, the 2025 results show they are currently in a transition phase. If you are looking for a stable, dividend-paying company that prioritizes long-term health over quick growth, this is a stock to watch as they pivot away from contract manufacturing and toward their own higher-margin products.